Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2a treatment

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 10, 2006, Pages 1235-1241

  Yildirim, Beytullah ^a   Durak, Haydar ^b   Ozaras, Resat ^b   Canbakan, Billur ^b   Ozkan, Perihan ^b   Ozbay, Gulsen ^b   Senturk, Hakan ^b  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Genotype; Hemodialysis; Hepatitis C; Interferon; Liver steatosis

Indexed keywords

CHOLESTEROL; RECOMBINANT ALPHA2A INTERFERON; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDEMIC DISEASE; EVALUATION; FATTY LIVER; FEMALE; FOLLOW UP; GENOTYPE; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIVER BIOPSY; MALE; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; TURKEY (REPUBLIC);

ADULT; AGED; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33748987054     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600670034     Document Type: Article

References (41)

1. Fabrizi F, Martin P. Hepatitis C virus infection in dialysis: an emerging clinical reality. Int J Artif Organs 2001;24:123-30.
2. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65:2335-42.
3. Leblebicioglu H, Gunaydin M, Cengiz K, Islek I. Hepatitis markers in hemodialysis patients. Microbiol Bul 1993;27:321-6.
4. Sahin I, Arabaci F, Sahin HA, Ilhan M, Ustun Y, Mercan R, et al. Does hepatitis C virus infection increase hematocrit and hemoglobin levels in hemodialyzed patients? Clin Nephrol 2003;60:401-4.
5. Koksal I, Biberoglu K, Biberoglu S, Koc F, Ayma Y, Aker F, et al. Hepatitis C virus antibodies among risk groups in Turkey. Infection 1991;19:228-9.
6. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993;44:1322-6.
7. McLaughlin K, Morris AJ. Antiviral treatment for HCV patients, pre-renal transplantation. Nephrol Dial Transplant 1997;12:1770-1.
8. Muller GY, Zabaleta ME, Arminio A, Colmenares CJ, Capriles FI, Bianco NE, et al. Risk factors for dialysis-associated hepatitis C in Venezuela. Kidney Int 1992;41:1055-8.
9. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001;21:435-40.
10. Fabrizi F, Locatelli F. Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist. Nephrol Dial Transplant 1999;14:2079-81.
11. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995;59:1426-31.
12. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
13. Ellis ME, Alfurayh O, Halim MA, Sieck JO, Ali MA, Bernvil SS, et al. Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol 1993;18:210-6.
14. Dhillon AP, Dusheiko GM. Pathology of hepatitis C virus infection. Histopathology 1995;26:297-309.
15. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-32.
16. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peg interferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
17. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
18. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002;97:2880-5.
19. Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001;39:119-24.
20. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
21. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106:686-90.
22. Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005;39:728-30.
23. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterology 2003;9:1610-5.
24. Daichou Y, Kurashige S, Hashimoto S, Suzuki S. Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron 1999;83:237-45.
25. Cohen G, Haag-Weber M, Horl WH. Immune dysfunction in uremia. Kidney Int Suppl 1997;62:79-82.
26. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001;88:120-6.
27. Chemello L, Alberti A, Rose K, Simmonds P. The hepatitis C serotype and response to interferon therapy. N Engl J Med 1994;330:143.
28. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, et al. Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Intern 1995;471:412-8.
29. Bozdayi G, Rota S, Verdi H, Derici U, Sindel S, Bali M, et al. The presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotype distribution. Mikrobiyol Bul 2002;36:291-300.
30. Abacioglu YH, Davidson F, Tuncer S, Yap PL, Ustacelebi S, Yulug N, et al. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995;2:297-301.
31. Fernandez JL, Rendo P, del Pino N, Viola L. A double-blind controlled trial of recombinant interferon alfa-2b in hemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hepatitis 1997;4:113-9.
32. Chan TM, Wu PC, Lau JY, Lok AS, Lai CL, Cheng IK. Interferon treatment for hepatitis C virus infection in patients on hemodialysis. Nephrol Dial Transplant 1997;12:1414-9.
33. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
34. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
35. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187-99.
36. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
37. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378-86.
38. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
39. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7.
40. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001;33:704-7.
41. Mekki K, Prost J, Bouchenak M, Remaoun M, Belleville J. Plasma lipoprotein lipase, hepatic lipase activities, VLDL, LDL compositions at different times of hemodialysis. Atherosclerosis 2003;169:269-77.